Galapagos

Pioneering For Patients

We are Galapagos

We are a biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life.

Our Intent to Separate into Two Publicly Traded Entities

On January 8, we announced a planned separation into two entities: Galapagos, which would continue to advance its global cell therapy leadership in addressing high unmet medical needs in oncology, and a newly to be formed company (“SpinCo”), which would focus on building a pipeline of innovative medicines through transformational transactions.

Read moreOur pipeline

Our Technology Platforms

Small Molecules

We are seeking partners to take over our small molecules’ assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.

Learn more

Our Technology Platforms

Cell Therapy

  • Scalable, decentralized, fast: stem-like, early memory cells near patients in median 7 days vein-to-vein
  • High-yielding discovery engine: multi-targeting, next-generation cell therapies
  • Diversify and grow: through partnerships and M&A
Discover more

LATEST PRESS RELEASES

More

STORIES OF PURPOSE

Pioneering for Patients, with Patients!

Patients and Carers

At Galapagos, we put patients’ care and well-being first and foremost.

Our goal is to improve patients’ quality of life through life-changing science and innovation.

Discover our commitment to pioneering for patients, with patients!

Discover our commitment